Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. METHODS: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed. RESULTS: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03). CONCLUSIONS: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials have shown that targeted inhibition of this inflammatory pathway, as measured by changes in CRP concentrations, can reduce the rate of cardiovascular events.5, 6, 7”
From Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was also not an isolated finding as a similar reduction of CVD risk linked to reduction of inflammation was reported in the COLCOT trial when participants were given low‐dose colchicine (a standard anti‐inflammatory drug) (Tardif et al., 2019).”
From Treatment of periodontitis and C ‐reactive protein: A systematic review and meta‐analysis of randomized clinical trials (2023) · cites this paper as Tardif et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“However, when appraised together, the evidence supports apolipoprotein B as being necessary for lipid-mediated atherogenesis by LDL-C to occur. 57,58 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [58]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
Ravelli, R. B. G., Gigant, B., Curmi, P. A., Jourdain, I., Lachkar, S., Sobel, A., & Knossow, M. (2004) · Nature · doi:10.1038/nature02393 · Cited by 1,630
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Self-citationLow-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,054
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.542738 · Cited by 614
Cited by
Items 201–300 of 1,006
Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm
Ferraro, R., Latina, J. M., Alfaddagh, A., Michos, E. D., Blaha, M. J., Jones, S. R., Sharma, G. V., Trost, J. C., Boden, W. E., Weintraub, W. S., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.078 · Cited by 131
Emerging views of statin pleiotropy and cholesterol lowering
Yu, D., & Liao, J. K. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab032 · Cited by 120
“In COLCOT, colchicine lowered the primary endpoint by 23% and cardiovascular death by 16%.(49) In CIRT, treatment with low-dose methotrexate failed to lower either CRP or the composite primary cardiovascular endpoint.”
BackgroundGeorgakis, M. K., van der Laan, S. W., Asare, Y., Mekke, J. M., Haitjema, S., Schoneveld, A. H., de Jager, S. C. A., Nurmohamed, N. S., Kroon, J., Stroes, E. S. G., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316091 · Cited by 116
“Multivariable models were used to explore associations of plaque levels of MCP-1 (1 SD increment) with (1) plaque protein levels of a panel of 24 cytokines and growth factors (thereafter called cytokines for simplicity) and activity of 3 MMPs, (2) histopathologic plaque vulnerability phenotypes, (3) presence of a symp…”
BackgroundMethodZhang, Y., Cai, Z., Shen, Y., Lu, Q., Gao, W., Zhong, X., Kang, Y., Yuan, J., & Liu, H. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01016-x · Cited by 115
Management of inflammation in cardiovascular diseases
Goswami, S. K., Ranjan, P., Dutta, R. K., & Verma, S. K. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105912 · Cited by 120
Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications
Vuong, J. T., Stein-Merlob, A. F., Nayeri, A., Sallam, T., Neilan, T. G., & Yang, E. H. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.048 · Cited by 125
NLRP3 inflammasome: The rising star in cardiovascular diseases
Zheng, Y., Li, X., Dong, N., & Li, F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.927061 · Cited by 129
Acute coronary syndromes: mechanisms, challenges, and new opportunities
Kraler, S. C., Mueller, C. E., Libby, P., & Bhatt, D. L. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf289 · Cited by 146
Arteriosclerosis e inflamación. Nuevos enfoques terapéuticos
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2020.04.024 · Cited by 125
Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies
Kessler, T., & Schunkert, H. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.04.001 · Cited by 123
Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease
Nishizawa, H., Maeda, N., & Shimomura, I. (2022) · Hypertension Research · doi:10.1038/s41440-021-00840-w · Cited by 112
Microtubules and cardiovascular diseases: insights into pathology and therapeutic strategies
Wu, Q., Wang, Y., Liu, J., Guan, X., Chang, X., Liu, Z., & Liu, R. (2024) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2024.106650 · Cited by 114
Inflammation in atherosclerosis: Lessons and therapeutic implications
Libby, P., & Soehnlein, O. (2025) · Immunity · doi:10.1016/j.immuni.2025.09.012 · Cited by 139
Inflammasomes and Atherosclerosis: a Mixed Picture
Tall, A. R., & Bornfeldt, K. (2023) · Circulation Research · doi:10.1161/circresaha.123.321637 · Cited by 117
He, H., Han, Q., Wang, S., Long, M., Zhang, M., Li, Y., Zhang, Y., & Gu, N. (2023) · ACS Nano · doi:10.1021/acsnano.3c01420 · Cited by 111
Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication
Antonopoulos, A. S., Angelopoulos, A., Papanikolaou, P., Simantiris, S., Oikonomou, E. K., Vamvakaris, K., Koumpoura, A., Farmaki, M., Trivella, M., Vlachopoulos, C. V., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.09.014 · Cited by 115
Wong, N. D., Toth, P. P., & Amsterdam, E. A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.013 · Cited by 106
Wang, H., Liu, Z., Shao, J., Lin, L., Jiang, M., Wang, L., Lu, X.-C., Zhang, H. S., Chen, Y., & Zhang, R. (2020) · Journal of Immunology Research · doi:10.1155/2020/4904217 · Cited by 131
“6 months Cardiovascular death, resuscitated cardiac arrest, myocardial infarction, stroke, hospitalization for emergency revascularization Yes [73]”
Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management
O’Dell, J. R., Brophy, M. T., Pillinger, M. H., Neogi, T., Palevsky, P. M., Wu, H., Davis‐Karim, A., Newcomb, J. A., Ferguson, R. E., Pittman, D., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100028 · Cited by 120
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K. P., & Tousoulis, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109080 · Cited by 120
Vulnerable or High-Risk Plaque
Vergallo, R., Park, S., Stone, G. W., Erlinge, D., Porto, I., Waksman, R., Mintz, G. S., D’Ascenzo, F., Seitun, S., Saba, L., et al. (2025) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.12.004 · Cited by 139
Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation
Weng, J., Koch, P. D., Luan, H. H., Tu, H.-C., Shimada, K., Ngan, I., Ventura, R., Jiang, R., & Mitchison, T. J. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00366-y · Cited by 111
Regulated Necrosis in Atherosclerosis
Puylaert, P., Zurek, M., Rayner, K. J., Meyer, G. R. Y. D., & Martinet, W. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318177 · Cited by 122
Li, J., Meng, X., Shi, F., Jing, J., Gu, H., Jin, A., Jiang, Y., Li, H., Johnston, S. C., Hankey, G. J., et al. (2024) · BMJ · doi:10.1136/bmj-2023-079061 · Cited by 131
“The 90 day duration of colchicine treatment in CHANCE-3 was 18 19 which concentrated on long term risk of cardiovascular events.”
BackgroundResultYang, M., Lv, H., Liu, Q., Zhang, L., Zhang, R., Huang, X., Wang, X., Han, B., Hou, S., Liu, D., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9173530 · Cited by 105
“5mg) significantly reduced the risk of ischemic cardiovascular events compared with the placebo group [14].”
BackgroundVerma, S., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Jensen, C., Kandler, K., Kushner, R. F., Rubino, D. M., & Kosiborod, M. N. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101737 · Cited by 106
Custodero, C., Ciavarella, A., Panza, F., Gnocchi, D., Lenato, G. M., Lee, J., Mazzocca, A., Sabbà, C., & Solfrizzi, V. (2022) · GeroScience · doi:10.1007/s11357-022-00556-w · Cited by 120
Schunk, S. J., Triem, S., Schmit, D., Zewinger, S., Sarakpi, T., Becker, E., Hütter, G., Wrublewsky, S., Küting, F., Hohl, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053547 · Cited by 107
Παπαδόπουλος, Α., Palaiopanos, K., Björkbacka, H., Peters, A., de Lemos, J. A., Seshadri, S. S., Dichgans, M., & Georgakis, M. K. (2021) · Neurology · doi:10.1212/wnl.0000000000013274 · Cited by 111
Clonal hematopoiesis in cardiovascular disease and therapeutic implications
Tall, A. R., & Fuster, J. J. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00015-3 · Cited by 105
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque
Marfella, R., Prattichizzo, F., Sardu, C., Paolisso, P., D’Onofrio, N., Scisciola, L., Grotta, R. L., Frigé, C., Ferraraccio, F., Panarese, I., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.971 · Cited by 108
Macrophage profiling in atherosclerosis: understanding the unstable plaque
Gianopoulos, I., & Daskalopoulou, S. S. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-023-01023-z · Cited by 108
“This has incredibly important implications, since the recent CANTOS [125], COLCOT [152], and LoDoCo2 [106, 107] trials have demonstrated the potential of immunotherapies to treat CV disease.”
Adinolfi, L. E., Petta, S., Fracanzani, A. L., Coppola, C., Narciso, V., Nevola, R., Rinaldi, L., Calvaruso, V., Staiano, L., Di Marco, V., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.01.010 · Cited by 98
Murray, E. C., Nosalski, R., MacRitchie, N. A., Tomaszewski, M., Maffia, P., Harrison, D. G., & Guzik, T. J. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab330 · Cited by 122
Modeling early stage atherosclerosis in a primary human vascular microphysiological system
Zhang, X., Bishawi, M. M., Zhang, G., Prasad, V., Salmon, E., Breithaupt, J. J., Zhang, Q., & Truskey, G. A. (2020) · Nature Communications · doi:10.1038/s41467-020-19197-8 · Cited by 109
Williams, S. A., Ostroff, R., Hinterberg, M. A., Coresh, J., Ballantyne, C. M., Matsushita, K., Mueller, C. E., Walter, J., Jonasson, C., Holman, R. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9625 · Cited by 97
Yalçınkaya, M., Liu, W., Thomas, L.-A., Olszewska, M., Xiao, T., Abramowicz, S., Papapetrou, E. P., Westerterp, M., Wang, N., Tabas, I. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.065344 · Cited by 111
Systematic Review on the Role of IL-6 and IL-1β in Cardiovascular Diseases
Katkenov, N., Mukhatayev, Z., Kozhakhmetov, S., Sailybayeva, A., Bekbossynova, M. S., & Kushugulova, A. R. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11070206 · Cited by 136
“Personalized medicine approaches, which tailor anti-inflammatory treatments based on individual patient profiles, including their inflammatory status, could further enhance the effectiveness of these interventions [2,26,41,44,45].”
BackgroundChertow, G. M., Chang, A. M., Felker, G. M., Heise, M. A., Velkoska, E., Fellström, B., Charytan, D. M., Clementi, R. A., Gibson, C. M., Goodman, S. G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03043-1 · Cited by 113
Amarenco, P. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp1908837 · Cited by 103
Trained Immunity in Atherosclerotic Cardiovascular Disease
Gomez, D. F., Bekkering, S., Netea, M. G., & Riksen, N. P. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314216 · Cited by 112
Colchicine’s Role in Cardiovascular Disease Management
Buckley, L. F., & Libby, P. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.319851 · Cited by 106
Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Sardu, C., Paolisso, G., & Marfella, R. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200213123029 · Cited by 99
Schunk, S. J., Kleber, M. E., März, W., Pang, S., Zewinger, S., Triem, S., Ege, P., Reichert, M., Krawczyk, M. J., Weber, S. N., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab107 · Cited by 106
“In addition to canakinumab, treatment with colchicine, which modulates the NLRP3 inflammasome, reduces CV events in patients post-MI with a stronger effect as compared to canakinumab.(12) Since treatment with canakinumab or colchicine is associated with potential serious adverse events, strategies to select patients f…”
BackgroundInfluentialSelf-citationRepurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis
Liu, W., Yalcinkaya, M., Maestre, I. F., Olszewska, M., Ampomah, P. B., Heimlich, J. B., Wang, R., Vela, P. S., Xiao, T., Bick, A. G., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00281-3 · Cited by 93
High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes
Denegri, A., & Boriani, G. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200717090334 · Cited by 113
What Is the Role of the Inflammation in the Pathogenesis of Heart Failure?
Castillo, E. C., Vázquez‐Garza, E., Yee-Trejo, D., García‐Rivas, G., & Torre‐Amione, G. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01382-2 · Cited by 109
Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation
Reyes‐Soffer, G., & Westerterp, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105689 · Cited by 101
Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease
Lacy, M., Bürger, C., Shami, A., Ahmadsei, M., Winkels, H., Nitz, K., van Tiel, C. M., Seijkens, T. T. P., Kusters, P. J. H., Karshovka, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23909-z · Cited by 98
Wang, S., Hu, S., Luo, X., Bao, X., Li, J., Liu, M., Lv, Y., Zhao, C., Zeng, M., Chen, X., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103964 · Cited by 103
Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment
Pellegrini, V., Grotta, R. L., Carreras, F., Giuliani, A., Sabbatinelli, J., Olivieri, F., Berra, C., Ceriello, A., & Prattichizzo, F. (2024) · Cells · doi:10.3390/cells13191662 · Cited by 119
“As mentioned above, the CANTOS [4], COLCOT [5], LoDoCo [6], and LoDoCo 2 [7] trials all enrolled a consistent number of subjects with prediabetes or T2D.”
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis
Samuel, M., Berry, C., Dubé, M., Köenig, W., Lopez-Sendon, J. L., Maggioni, A. P., Pinto, F. J., Roubille, F., & Tardif, J. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf174 · Cited by 117
“7,15,20 A trend towards a reduction in a composite of recurrent non-fatal ischaemic stroke, MI, cardiac arrest, vascular death or hospitalization for unstable angina was detected among patients randomized to colchicine compared with placebo (HR, .84; 95% CI, .68–1.05).”
InfluentialSelf-citationCerebrovascular Disease and Cognition in Chronic Kidney Disease Patients
Miglinas, M., Cesniene, U., Janusaite, M. M., & Vinikovas, A. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00096 · Cited by 101
Atherosclerotic plaque stabilization and regression: a review of clinical evidence
Sarraju, A., & Nissen, S. E. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00979-8 · Cited by 122
Wang, Q., Oliver-Williams, C., Raitakari, O. T., Viikari, J., Lehtimäki, T., Kähönen, M., Järvelin, M.-R., Salomaa, V., Perola, M., Danesh, J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa972 · Cited by 89
“Recent genetic studies and randomized controlled trials indicate a causal role for inflammation in CVDs, including findings from genetic studies of the interleukin-6 receptor and phase III clinical trials of antiinflammatory drugs for the treatment of CHD, such as CANTOS trial of canakinumab,(15) a monoclonal antibody…”
BackgroundD’Alessandro, E., Becker, C., Bergmeier, W., Bode, C., Bourne, J. H., Brown, H. C., Buller, H. R., ten Cate‐Hoek, A. J., ten Cate, V., van Cauteren, Y. J. M., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1708035 · Cited by 100
Platelets as therapeutic targets to prevent atherosclerosis
Nording, H., Baron, L., & Langer, H. F. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.05.018 · Cited by 91
Cardiovascular Disease in Myeloproliferative Neoplasms
Leiva, O., Hobbs, G. S., Ravid, K., & Libby, P. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.04.002 · Cited by 110
Colchicine prevents accelerated atherosclerosis in TET2 -mutant clonal haematopoiesis
Zuriaga, M. A., Yu, Z., Matesanz, N., Truong, B. M. T., Ramos-Neble, B. L., Lopez, M., Uddin, M. M., Nakao, T., Niroula, A., Zorita, V., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae546 · Cited by 111
Mazhar, F., Faucon, A., Fu, E. L., Szummer, K. E., Mathisen, J., Gerward, S., Reuter, S. B., Marx, N., Mehran, R., & Carrero, J. J. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae557 · Cited by 99
Samuel, M., Tardif, J., Khairy, P., Roubille, F., Waters, D. D., Grégoire, J. C., Pinto, F. J., Maggioni, A. P., Díaz, R., Berry, C., et al. (2020) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaa045 · Cited by 91
“5 mg once daily) to standard-of-care medical therapy decreased the incidence of the primary composite endpoint of cardiovascular death, resuscitated cardiac arrest, MI, stroke, and urgent hospitalization for angina leading to coronary revascularization.(9) Colchicine is a well-established medication, but whether the r…”
BackgroundMethodInfluentialSelf-citationAssociation of Circulating Monocyte Chemoattractant Protein–1 Levels With Cardiovascular Mortality
Georgakis, M. K., de Lemos, J. A., Ayers, C. R., Wang, B., Björkbacka, H., Pana, T. A., Thorand, B., Sun, C., Fani, L., Malik, R., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.5392 · Cited by 92
Inflammation and Cardiovascular Disease: The Future
Arnold, N., Lechner, K., Waldeyer, C., Shapiro, M. D., & Köenig, W. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.50 · Cited by 95
Busque, L., Sun, M., Buscarlet, M., Ayachi, S., Feroz Zada, Y., Provost, S., Bourgoin, V., Mollica, L., Meisel, M., Hinterleitner, R., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000770 · Cited by 87
“Furthermore, the recent demonstration that utilization of a low dose of the antiinflammatory drug colchicine reduces cardiovascular events after MI may further justify the prospective evaluation of such approaches in CHIP carriers.(42) This study also allowed us to make additional observations.”
ResultSelf-citationChen, J., Wu, Q., Liu, H., Hu, W., Zhu, J., Ji, Z., & Yin, J. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.015 · Cited by 116
Assessing Cardiovascular Risk by Using the Fat Attenuation Index in Coronary CT Angiography
Klüner, L. V., Oikonomou, E. K., & Antoniades, C. A. (2021) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.2021200563 · Cited by 96
“The subsequent Colchicine Cardiovascular Outcomes Trial further showed that colchicine, when given to patients with a recent MI, reduces the incidence of ischemic cardiovascular events compared with placebo (24).”
BackgroundLacunar stroke: mechanisms and therapeutic implications
Yaghi, S. R., Raz, E., Yang, D., Cutting, S., Grory, B. M., Elkind, M. S. V., & de Havenon, A. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326308 · Cited by 110
The AIM2 inflammasome: A novel biomarker and target in cardiovascular disease
Du, L., Wang, X., Chen, S., & Guo, X. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106533 · Cited by 95
Conen, D., Wang, M. K., Popova, E., Chan, M. T. V., Landoni, G., Cata, J. P., Reimer, C., McLean, S. R., Srinathan, S. K., Trujillo-Reyes, J. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01689-6 · Cited by 98
Clinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 89
Role of Extracellular Vesicles in the Pathogenesis of Vascular Damage
Buffolo, F., Monticone, S., Camussi, G., & Aïkawa, E. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.17957 · Cited by 91
“Inflammatory response is now recognized as valuable target for the reduction of cardiovascular events, as demonstrated by the efficacy of colchicine and the IL-1β inhibitor canakinumab for secondary prevention 26,27 .”
The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches
Tsioufis, P., Theofilis, P., Tsioufis, K. P., & Tousoulis, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415937 · Cited by 103
Targeting inflammation to reduce recurrent stroke
Zietz, A., Gorey, S., Kelly, P. J., Mira, K., & McCabe, J. J. (2023) · International Journal of Stroke · doi:10.1177/17474930231207777 · Cited by 96
“66 In a subsequent meta-analysis of four RCTs (Supplemental Material), colchicine reduced the risk of MACE by 26%, with supportive direction of effect for MI and revascularization, but not cardiovascular death.”
BackgroundRomeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 109
Self-citationResidual cardiovascular risk: When should we treat it?
Gómez-Delgado, F., Raya‐Cruz, M., Katsiki, N., Delgado‐Lista, J., & Pérez‐Martínez, P. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.10.013 · Cited by 92
Akrami, M., Izadpanah, P., Bazrafshan, M., Hatamipour, U., Nouraein, N., Drissi, H. B., & Manafi, A. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02393-9 · Cited by 94
“[13] reported higher frequency of diarrhea as the commonest gastrointestinal symptom observed in patients who received colchicine than controls without any significant correlation in separate studies.”
BackgroundMethodAtherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches
Khan, A. W., & Jandeleit-Dahm, K. A. M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01115-w · Cited by 106
“The results of the COLCOT and the LoDoCo2 clinical trials 166,167 confirmed the cardiovascular benefits of colchicine in patients after myocardial infarction and in patients with chronic stable coronary artery disease, respectively.”
Nidorf, S. M., Fiolet, A. T. L., & Abela, G. S. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.07.003 · Cited by 79
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
Brunetti, L., Diawara, O., Tsai, A., Firestein, B. L., Nahass, R., Poiani, G. J., & Schlesinger, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092961 · Cited by 82
“Recent colchicine studies showing its efficacy in preventing major cardiovascular adverse events among patients who suffered a recent myocardial infarction compared with placebo is, therefore, of importance [6].”
BackgroundHigh lipoprotein(a): Actionable strategies for risk assessment and mitigation
Reyes‐Soffer, G., Yeang, C., Michos, E. D., Boatwright, W., & Ballantyne, C. M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100651 · Cited by 94
“The RCTs Low-Dose Colchicine (LoDoCo1, LoDoCo2) [131,132] and the Colchicine Cardiovascular Outcomes Trial (COLCOT) [133] have demonstrated that the risk of CV events is significantly lower with once daily colchicine compared to placebo in secondary prevention CVD populations.”
BackgroundGuía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 124
Thomas, P. E., Vedel‐Krogh, S., Kamstrup, P. R., & Nordestgaard, B. G. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad055 · Cited by 85
Low-dose colchicine for atherosclerosis: long-term safety
Nidorf, S. M., Ben‐Chetrit, E., & Ridker, P. M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae208 · Cited by 83
Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases
Potere, N., Bonaventura, A., & Abbate, A. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.319980 · Cited by 93
Psoriatic arthritis and the association with cardiometabolic disease: a narrative review
Karmacharya, P., Ogdie, A., & Eder, L. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x21998279 · Cited by 91
Li, Y., Che, J., Chang, L., Guo, M., Bao, X., Mu, D., Sun, X., Zhang, X., Lu, W., & Xie, J. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101788 · Cited by 117
Immune cells in cardiac homeostasis and disease: emerging insights from novel technologies
Steffens, S., Nahrendorf, M., & Madonna, R. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab842 · Cited by 89
Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis
Lorey, M. B., Öörni, K., & Kovanen, P. T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.841545 · Cited by 97
Uncoupling the Vicious Cycle of Mechanical Stress and Inflammation in Calcific Aortic Valve Disease
Dayawansa, N. H., Baratchi, S., & Peter, K. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.783543 · Cited by 88
“Further trials of the anti-inflammatory drug colchicine have also demonstrated a reduction in major adverse cardiovascular events in patients at high risk of myocardial infarction (186, 187).”
BackgroundSolomon, D. H., Giles, J. T., Liao, K. P., Ridker, P. M., Rist, P. M., Glynn, R. J., Broderick, R., Lu, F., Murray, M., Vanni, K. M. M., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223302 · Cited by 89
Ryan, T. A. J., Hooftman, A., Rehill, A. M., Johansen, M. D., Brien, E. C. O., Toller-Kawahisa, J. E., Wilk, M. M., Day, E. A., Weiss, H. J., Sarvari, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39174-1 · Cited by 84
Small, A. M., Peloso, G. M., Linefsky, J., Aragam, J., Galloway, A., Tanukonda, V., Wang, L.-C., Yu, Z., Sunitha Selvaraj, M., Farber-Eger, E. H., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.061451 · Cited by 76
Forkosh, E., Kenig, A., & Ilan, Y. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.616 · Cited by 81
NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases
Mezzaroma, E., Abbate, A., & Toldo, S. A. (2021) · Molecules · doi:10.3390/molecules26040976 · Cited by 85
“It also reduced the infiltration of neu‐ trophils and macrophages as well mRNA expression of pro‐inflammatory cytokines and NLRP3 inflammasome components 24 h after myocardial infarction [123].”
BackgroundMethodThe Role of the Inflammasome in Heart Failure
Wu, J., Dong, E., Zhang, Y., & Xiao, H. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.709703 · Cited by 81
Anzai, A., Ko, S., & Fukuda, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095214 · Cited by 88
Sagris, Μ., Apostolos, A., Theofilis, P., Ktenopoulos, N., Katsaros, O., Tsalamandris, S., Tsioufis, K. P., Toutouzas, K. P., & Tousoulis, D. (2024) · Biomedicines · doi:10.3390/biomedicines12040802 · Cited by 96
“During an approximately two-year follow-up, patients treated with colchicine suffered from significantly less MACE compared to the placebo arm [96].”
BackgroundAssociations of Adiposity, Circulating Protein Biomarkers, and Risk of Major Vascular Diseases
Pang, Y., Kartsonaki, C., Lv, J., Fairhurst-Hunter, Z., Millwood, I. Y., Yu, C., Guo, Y., Chen, Y., Bian, Z., Yang, L., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.6041 · Cited by 75
Immune System and Microvascular Remodeling in Humans
Rizzoni, D., Ciuceis, C. D., Szczepaniak, P., Paradis, P., Schiffrin, E. L., & Guzik, T. J. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.17955 · Cited by 88
Metadata
- Authors
- Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M.-A., Dubé, M.-P., Rhainds, D., Provencher, M., Blondeau, L., Orfanos, A., L’Allier, P. L., Guertin, M.-C., & Roubille, F.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- From the Montreal Heart Institute (J.-C.T., R.I., J.C.G., M.-A.L., M.-P.D., D.R., P.L.L.) and the Montreal Health Innovations Coordinating Center (M.P., L.B., A.O., M.-C.G.), Montreal, Centre Hospitalier Régional de Lanaudière, Joliette (S.K.), and Institut de Cardiologie et Pneumologie de Québec, Quebec City (O.F.B.) — all in Canada; San Francisco General Hospital, San Francisco (D.D.W.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); Associazione Nazionale Medici Cardiologi...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-12-26
- Volume
- 381
- Issue
- 26
- Pages
- 2497-2505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2986700515
- Cited by
- 3,159
- References
- 20
- Citations by year
- 2026: 505 · 2025: 519 · 2024: 445 · 2023: 415 · 2022: 414 · 2021: 485 · 2020: 361 · 2019: 10
- FWCI
- 230.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Funders
- Government of Quebec
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- colchicine, myocardial infarction, anti-inflammatory therapy, inflammation in atherosclerosis, cardiovascular mortality, major adverse cardiovascular events, stroke, angina pectoris, diarrhea, pneumonia, drug safety, low-dose colchicine, secondary prevention, coronary revascularization, cardiac arrest, myocardial infarction recurrence, cardiovascular risk reduction, cost-effectiveness, quality of life
- MeSH terms
- Aged, Angina Pectoris, Anti-Inflammatory Agents, C-Reactive Protein, Cardiovascular Diseases, Colchicine, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Recurrence, Biomarkers, Incidence, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate, Intention to Treat Analysis, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

